Literature DB >> 29570103

Invitation strategies and coverage in the population-based cancer screening programmes in the European Union.

Diama B Vale1, Ahti Anttila2, Antonio Ponti3, Carlo Senore3, Rengaswamy Sankaranaryanan4, Guglielmo Ronco3, Nereo Segnan3, Mariano Tomatis3, Maja P Žakelj5, Klara M Elfström6, Stefan Lönnberg7,8, Joakim Dillner9, Partha Basu4.   

Abstract

The aim of this study was to describe the compliance of the population-based cancer screening programmes in the European Union Member States to the invitation strategies enumerated in the European Guidelines and the impact of such strategies on the invitational coverage. Experts in screening programme monitoring from the respective countries provided data. Coverage by invitation was calculated as the proportion of individuals in the target age range receiving a screening invitation over the total number of annualized eligible population. The invitation strategies of 30 breasts, 25 cervical and 27 colorectal national or regional population-based screening programmes are described. Individual mail invitations are sent by 28 breasts, 20 cervical and 25 colorectal screening programmes. Faecal occult blood test kits are sent by post in 17 of the colorectal cancer screening programmes. The majority of programmes claimed to have a population registry, although some use health insurance data as the database for sending invitations. At least 95% invitation coverage was reached by 16 breast, six cervical and five colorectal screening programmes. Majority of the programmes comply with the invitation strategies enumerated in the European guidelines, although there is still scope for improvements. Coverage by invitation is below the desirable level in many population-based cancer screening programmes in European Union.

Entities:  

Mesh:

Year:  2019        PMID: 29570103     DOI: 10.1097/CEJ.0000000000000426

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  5 in total

1.  Colorectal cancer screening by fecal immunochemical test or colonoscopy in France: how many people are actually covered? Focus on the Provence-Alpes-Côte d'Azur region.

Authors:  Jean-François Seitz; David Lapalus; Sylvie Arlotto; Stéphanie Gentile; Florence Ettori; Yves Rinaldi; Philippe Grandval; Patrick Delasalle
Journal:  Eur J Gastroenterol Hepatol       Date:  2022-04-01       Impact factor: 2.566

2.  Cervical Cancer in the Baltic States: Can Intelligent and Personalized Cancer Screening Change the Situation?

Authors:  Mindaugas Stankūnas; Kersti Pärna; Anna Tisler; Anda Ķīvīte-Urtāne; Una Kojalo; Jana Zodzika; Nicholas Baltzer; Jan Nygard; Mari Nygard; Anneli Uuskula
Journal:  Acta Med Litu       Date:  2022-06-29

3.  "Clicks, likes, shares and comments" a systematic review of breast cancer screening discourse in social media.

Authors:  Bence Döbrössy; Edmond Girasek; Anna Susánszky; Zsuzsa Koncz; Zsuzsa Győrffy; Virág Katalin Bognár
Journal:  PLoS One       Date:  2020-04-15       Impact factor: 3.240

4.  The Cost-Effectiveness Analysis of Cervical Cancer Screening Using a Systematic Invitation System in Lithuania.

Authors:  Justina Paulauskiene; Mindaugas Stelemekas; Rugile Ivanauskiene; Janina Petkeviciene
Journal:  Int J Environ Res Public Health       Date:  2019-12-11       Impact factor: 3.390

Review 5.  The Effects of Different Invitation Schemes on the Use of Fecal Occult Blood Tests for Colorectal Cancer Screening: Systematic Review of Randomized Controlled Trials.

Authors:  Laura F Gruner; Efrat L Amitay; Thomas Heisser; Feng Guo; Tobias Niedermaier; Anton Gies; Michael Hoffmeister; Hermann Brenner
Journal:  Cancers (Basel)       Date:  2021-03-25       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.